Gabapentin API

Name	Gabapentin
Chinese name	加巴喷丁酯
Cas Number	478296-72-9
Source	India
Qualifications	USDMF/-/-/-/-

Gabapentin Ennacarbi was originally developed by XenoPort in the United States on the basis of gabapentin for the treatment of restless legs syndrome. In April 2011, it was approved by the FDA for marketing. Gabapentin Ennacarbi is a prodrug of gabapentin, which can overcome the defects of gabapentin in pharmacokinetics. It is rapidly hydrolyzed into gabapentin by non-specific esterase in the body and exerts pharmacological effects. The efficacy of gabapentin ennacarb is similar to that of dopamine receptor agonists, but no enhancement has been seen in clinical trials, and other adverse reactions are relatively mild. This is where it is superior to dopamine receptor agonists; gabapentin ennacar Another advantage of the ratio is: clinical trials have shown that it can improve sleep quality, reduce sleep disorders, and reduce daytime sleepiness symptoms. As sleep is improved, patients' anxiety and depression and other bad moods are also significantly improved. Therefore, gabapentin and enakabi are likely to replace dopamine receptor agonists as the first-line drug for the clinical treatment of restless legs syndrome.

Hot Tags: gabapentin api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Edoxaban API, Letrozole API, Solinasine Succinate API, Pleasant API, Rasagiline Mesylate API, Adapalene API

• Previous: Ebastine API
• Next: Fulvestrant API